pancreatic cancer
Conditions
Interventions
Case series:Apatinib combined with Tego
Sponsors
Changzhou Second People's Hospital of Jiangsu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. adults aged 18-70 years (including 18 and 70 years of age); 2. ECOG score: 0-2 points (see Appendix 2); 3. the survival period is more than 12 weeks; 4. with histologicaly confirmed metastatic or locally advanced non resectable pancreatic cancer, at least one measurable and longest diameter greater than 10 mm was found in the study group according to the RECIST1.1 standard; 5. front-line medication should include at least one chemotherapy based on gemcitabine, with no more than 2 chemotherapy regimens (the number of chemotherapy schemes is less than 2); 6. the main organs are functioning normally, that is, they meet the following criteria: (1) the standard of blood routine examination should conform to (no transfusion and blood products within 14 days, without G-CSF and other hematopoietic stimulating factors): HB > 80 g/L; ANC > 1.5 x 10^9/L; PLT > 90 x 10^9/L; (2) biochemical examination should comply with the following criteria: TBIL<1.5ULN; ALT and AST<2.5ULN, while for liver metastases, < 5ULN; The serum Cr was less than 1.5ULN; plasma albumin was more than 30g/L; 7. women of childbearing age must adopt reliable contraception measures or carry out pregnancy tests (serum or urine) within the first 7 days of the group, and have negative results, and are willing to use appropriate methods for contraception 8 weeks after the trial and the last trial; 8. swallowing function is normal, oral test drugs can be taken without gastrointestinal absorption dysfunction; 9. the volunteers voluntarily joined the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. anaphylaxis to apatinib or teggio; 2. there are various factors that affect oral medication (including dysphagia, chronic diarrhea, intestinal obstruction, etc.). 3. abnormal coagulation function (INR>1.5, APTT>ULN); 4. combined severe heart disease including: (1) angina pectoris; (2) drug treatment or clinical arrhythmia (including abnormal baseline electrocardiogram, male QTc interval > 450ms, female QTc interval > 470ms); (3) myocardial infarction; (4) heart failure; (5) left ventricular ejection fraction (LVEF) 140mmHg, diastolic blood pressure >90mmHg) and urinary protein positive patients; 6. combined with other serious medical diseases, including cerebrovascular disease, uncontrolled infection, active peptic ulcer, etc. 7. there were central nervous system metastasis of tumor. 8. women in pregnancy and lactation; 9. in the past 5 years, the patient had been diagnosed with other tumors. 10. the last chemotherapy time was shorter than 4 weeks, and the last radiotherapy was shorter than 4 weeks. 11. the interval between the use of pre test drugs or any listed antitumor drugs is less than 28 days or 5 half-life (taking the time elders). 12. due to the use of antineoplastic drugs, 2 or more toxicities were not recovered. 13. suffering from mental illness or history of psychotropic substance abuse. 14. researchers think it is not appropriate to participate in the experimenter.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival;Duration of response;Objective response rate;Disease Control Rate; | — |
Countries
China
Contacts
Public ContactKequn Xu
Changzhou Second People's Hospital
Outcome results
None listed